Gayatri BioOrganics Ltd Q3 FY26: ₹0 Revenue, ₹-0.22 Cr Loss, ROCE -40.7% — Is This a Company or a Time Capsule?

---

1. At a Glance – The Zero-Sales Chemical Empire

Here’s a plot twist Bollywood wouldn’t dare write.

Gayatri BioOrganics Ltd currently trades at ₹13.8, with a market cap of ₹109 crore. Over the last 1 year, the stock has jumped 98.3%. Over 3 months, it’s up 16.3%. Momentum investors must be feeling like geniuses.

Now the uncomfortable part.

Latest quarterly sales: ₹0.00 crore.
Latest quarterly PAT: ₹-0.22 crore.
TTM Sales: ₹0.00 crore.
TTM PAT: ₹-0.86 crore.
ROCE: -40.7%.
Book Value: ₹-4.62.
Debt: ₹37.3 crore.

Yes, you read that correctly. A ₹109 crore market cap company generating zero revenue. That’s not “asset light.” That’s “activity light.”

And yet, the stock has delivered multibagger returns in one year.

So the real question is:

Are we looking at a sleeping revival candidate…
Or a listed shell waiting for destiny?

Let’s investigate like a financial detective with a magnifying glass and mild suspicion.

---

2. Introduction – The Starch Story That Lost Its Starch

Back in 1993, Gayatri Bio-Organics was incorporated to manufacture starch and starch derivatives. Sorbitol. Liquid glucose. Corn fiber. Gluten. Fancy sounding bio-products.

Everything a carbohydrate enthusiast could dream of.

Then came FY19.

During FY19, the company transferred its assets to Bluecraft Agro Private Ltd under a Business Transfer Agreement via slump sale.

Translation?

The operating business was sold.

Since then, revenue generation has essentially vanished. The company itself states:

Due to the BTA agreement, company has not reported any revenue.

So what are we left with?

A listed entity.
Some borrowings.
Negative reserves.
And “pursuing various options for future course of action.”

Which is corporate language for:
“We’re figuring it out.”

And somehow, the stock doubled in one year.

Are markets betting on a reverse merger?
A restructuring?
A hidden asset play?

Or is this just pure speculation doing bhangra?

Let’s go deeper.

---

3. Business Model – WTF Do They Even Do?

Before FY19, business was straightforward:

• Manufacture starch
• Process maize
• Produce sorbitol
• Supply glucose derivatives
• Crush maize at 54,000 MTPA
• Produce sorbitol at 8,550 MTPA

Two manufacturing units in Andhra Pradesh.

Classic commodity chemical story.

Then… slump sale.

Assets transferred.
Operations gone.
Revenue disappeared.

Currently?

There is no disclosed operating revenue model. The company is “pursuing options.”

So effectively, today’s business model is:

• Maintain listing
• Pay interest
• Report losses
• Attend board meetings
• Publish quarterly results
• Explore future possibilities

This is no longer a starch manufacturer.

This is a strategic waiting room.

Now ask yourself:
Is the market valuing what exists… or what might exist?

---

4. Financials Overview – The Quarterly Reality Check

Q1 FY26 EPS: -0.03
Q2 FY26 EPS: -0.03
Q3 FY26 EPS: -0.03

Average EPS = (-0.03 -0.03 -0.03) / 3 = -0.03

Annualised EPS = -0.03 × 4 = -0.12

Now let’s compare.

Quarterly Financial Comparison (₹ in Crores)

Metric	Latest Q3 FY26	Q3 FY25	Q2 FY26	YoY %	QoQ %
Revenue	0.00	0.00	0.00	0%	0%
EBITDA	-0.13	-0.16	-0.12	NA	NA
PAT	-0.22	-0.16	-0.21	-37.5%	-4.8%
EPS (₹)	-0.03	-0.02	-0.03	-50%	0%

Witty observation:

Revenue flat.
Loss steady.
Interest expense climbing.
Consistency? 10/10.
Profitability? We’ll get back to you.

Now let’s calculate P/E.

Annualised EPS = -0.12
CMP = ₹13.8

P/E = 13.8 / (-0.12) = Negative

So P/E does not exist